evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2 questions · 2 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Target of rapamycin inhibitors (TOR‐I) vs calcineurin inhibitors (CNI): secondary outcomes

New onset of diabetes · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) showed no clear difference in new‐onset diabetes mellitus compared with calcineurin inhibitors (CNI): secondary outcomes (moderate certainty).

1 finding from 1 review

Target of rapamycin inhibitors (TOR‐I) vs antimetabolites: secondary outcomes

New onset of diabetes · primary immunosuppression in kidney transplant recipients

Target of rapamycin inhibitors (TOR‐I) probably leads to higher new‐onset diabetes mellitus compared with antimetabolites: secondary outcomes (moderate certainty).

1 finding from 1 review